Understanding how lipid nanoparticles can improve cancer therapies and COVID-19 vaccines
Official title: Characterizing DC-specific mechanisms of LNP immunogenicity to enhance LNP-based anti-tumor therapies
Funded at Icahn School of Medicine at Mount Sinai · NIH-10994716 · Data updated 2026-11-12
This study is looking at how tiny particles called lipid nanoparticles can help boost the immune system, especially by working with special immune cells, to make cancer treatments and COVID-19 vaccines more effective for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 15, 2024 |
| Project end | July 14, 2027 |
| Funding year | 2024 |
| Award (this year) | $42,724 |
| NIH project number | 1F30CA287638-01A1 |
| Project ID | NIH-10994716 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit include individuals with cancer or those seeking enhanced protection against COVID-19.
✕Less likely to help
Patients who are not affected by cancer or COVID-19 may not receive any benefit from this research.
What this research studies
This research investigates the mechanisms by which lipid nanoparticles (LNPs) can enhance immune responses, particularly focusing on dendritic cells that play a crucial role in activating the immune system. By analyzing how different formulations of LNPs interact with these immune cells, the study aims to optimize LNPs for better targeting and effectiveness in both cancer treatments and COVID-19 vaccines. Patients may benefit from improved therapies that harness the power of their immune systems more effectively against tumors and viral infections.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies and improved COVID-19 vaccines that better stimulate the immune response.
How similar studies have gone: Previous research has shown promising results in using lipid nanoparticles for vaccine delivery, indicating potential success for this approach.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Moon, Chang Yoon — Icahn School of Medicine at Mount Sinai
- Study coordinator: Moon, Chang Yoon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.